Navigation Links
Hepatitis C Drug Market: Forecasts for 9 Countries, Players' (Current and Future) Analysis in New Research Reports
Date:6/13/2013

DALLAS, June 13, 2013 /PRNewswire-iReach/ -- RnRMarketResearch.com now offers new market research reports on the Hepatitis C Virus drug industry for US, Japan, Brazil China, France, Germany, Italy, Spain and the UK with an in-depth analysis on the companies in these countries. There is no effective vaccine against HCV, so the market is driven by therapeutics. Currently, drug combinations containing pegylated interferon (e.g., Roche's Pegasys and Merck's PegIntron) and ribavirin (e.g., Roche's Copegus and Merck's Rebetol) are used to treat HCV infection. Patients infected with HCV genotype 1 can also have a protease inhibitor added to their combination therapy, such as Merck's Victrelis (boceprevir) or Vertex's Incivek (telaprevir).

(Photo: http://photos.prnewswire.com/prnh/20130613/CG31482)

In United States, the projected drivers of HCV drug market growth include increased patient awareness of HCV, broader HCV screening recommendations, the shift in American medicine toward preventative care, and the launch of next-generation HCV therapies. The report "PharmaPoint: Hepatitis C Virus – United States Drug Forecast and Market Analysis" (http://www.rnrmarketresearch.com/pharmapoint-hepatitis-c-virus-united-states-drug-forecast-and-market-analysis-market-report.html) says Vertex's Incivek is the current market leader. It was among the first DAA HCV therapies launched in the US. Incivek's improved efficacy over the previous standard of care (i.e., peginterferon and ribavirin combination therapy) in the treatment of the most
'/>"/>

SOURCE RnRMarketResearch.com
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Aethlon Medical Note: An Unprecedented Data Point, The Single-Treatment Capture of Hepatitis C Virus (HCV) by the Aethlon Hemopurifier®
2. Aethlon Medical Reports Undetectable Hepatitis C Virus (HCV) in Genotype 1, Genotype 3, and Genotype 5 Patients Treated with Hemopurifier® Therapy
3. Bulgaria Launches Development of National Hepatitis Plan
4. Major Breakthrough in Hepatitis C Vaccine Development
5. Aethlon Medical Discusses Therapeutic Device Strategies to Address Cancer, Hepatitis-C and Sepsis with the Wall Street Transcript
6. Janssen Announces Collaboration with Vertex on Phase 2 Study to Investigate an All-Oral Regimen of Simeprevir (TMC435) and VX-135 for Treatment of Hepatitis C
7. Aethlon Medical Receives Intent to Issue Notice on European Patent to Remove Hepatitis C Virus (HCV), Human Immunodeficiency Virus (HIV), and Other Viral Pathogens From Blood
8. Efficacy and Safety Data from Phase 2B Trials of Janssens Simeprevir in Hepatitis C Patients with Advanced Fibrosis of the Liver Presented at Annual Meeting of the American Association for the Study of Liver Diseases
9. Phase 2b Data of Boehringer Ingelheims Interferon-Free Hepatitis C Treatment Show Viral Cure Achieved in Up to 85% of Treatment-Naive Patients
10. Boehringer Ingelheim Enrolls First Patients in Pivotal Phase 3 Interferon-Free Hepatitis C Trial Program
11. Computer Modeling Reveals How Surprisingly Potent Hepatitis C Drug Works
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)...  According to data released today by the Centers ... Medicare Part D premium is expected to remain stable ... projected, the Pharmaceutical Care Management Association (PCMA) said. ... a bright spot in American health care. By offering ... using cutting edge, cost-saving tools like pharmacy networks and ...
(Date:7/31/2014)... Tandem Diabetes Care®, Inc. (NASDAQ: TNDM ), a ... today reported its financial results for the quarter ended June ... of 2014 to the same period of 2013: , ... , t:slim Pump shipments grew 64 percent to 2,235 ... ended June 30, 2014 to the same period of 2013: ...
(Date:7/31/2014)... July 31, 2014  Alexza Pharmaceuticals, Inc. (Nasdaq: ... on its pipeline and new product development efforts. In ... initiate a Phase 2a study of AZ-002 (Staccato ... the management of patients with acute repetitive seizures. ... -based product candidates for development - AZ-008 and ...
Breaking Medicine Technology:Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 2Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 3Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 4Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 5Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 6Alexza Provides Pipeline Update 2Alexza Provides Pipeline Update 3Alexza Provides Pipeline Update 4Alexza Provides Pipeline Update 5Alexza Provides Pipeline Update 6
... Pharmaceuticals, Inc. (NYSE: WPI ), today confirmed ... of Delaware has ruled that Watson,s generic version of ... No. 6,264,981 (the ,981 Patent).  The Company said that ... all available options, including an appeal. ...
... 25, 2011 Approximately five percent of prescriptions submitted ... a 30-day period during 2009 included a "dispense as ... patients demand the dispensing of a specific brand-name drug ... care system up to $7.7 billion annually, according to ...
Cached Medicine Technology:Watson Confirms District Court Ruling in Generic Fentora® Patent Suit 2CVS Caremark Research Finds "Dispense as Written" Prescriptions May Add $7.7 Billion to Annual Health Care Costs 2CVS Caremark Research Finds "Dispense as Written" Prescriptions May Add $7.7 Billion to Annual Health Care Costs 3
(Date:8/1/2014)... use among young people has spiked, with 29.3 percent ... at least once and 17 percent admitting to regular use ... ‘Yes to Life,’ volunteers from the Church of Scientology of ... information about drugs, to help reverse this alarming trend. , ... Say ‘Yes’ to Life,” volunteers have distributed 40,000 copies of ...
(Date:8/1/2014)... the University of California, San Diego School of Medicine ... chili peppers produces chronic activation of a receptor ... reaction that ultimately reduces the risk of colorectal tumors. ... 2014 issue of The Journal of Clinical Investigation ... was originally discovered in sensory neurons, where it acts ...
(Date:8/1/2014)... regulating appetite and whole-body metabolism. A protein known as ... intake and body weight, but the identity of the ... A new study in the Journal of Clinical ... of neuron known as pro-opiomelanocortin (POMC) neurons is critical ... Diano and colleagues at Yale University School of Medicine ...
(Date:8/1/2014)... Bronson Gray HealthDay Reporter FRIDAY, ... work in manufacturing jobs may have significantly less endurance than those ... of 32 people -- half were obese, half were of normal ... were about 60 percent longer. Obesity also was associated with ... Being older -- 50 to 65 years of age -- ...
(Date:8/1/2014)... The U.S. Food and Drug Administration announced on Friday ... fight type 2 diabetes. Jardiance (empagliflozin) "can ... to control blood sugar levels in the overall management ... of Drug Evaluation II in the FDA,s Center for ... The FDA also recommended that Jardiance be used ...
Breaking Medicine News(10 mins):Health News:Addressing a Serious Issue Affecting German Teens 2Health News:Pepper and halt: Spicy chemical may inhibit gut tumors 2Health News:Obesity Might Slow You Down at Work 2Health News:Obesity Might Slow You Down at Work 3Health News:FDA Approves New Type 2 Diabetes Drug 2
... standards for elder care in nursing homes are the only ... to prevent serious safety violations, according to a new study ... ,The majority of the nation's elderly and disabled in ... national recommendations for safe care, the study found. While no ...
... approved Torisel (temsirolimus) for the treatment of a certain type ... Torisel was approved based on a study that showed use ... carcinoma. The drug is an enzyme inhibitor, a protein that ... ,'We have made significant advances in the battle against kidney ...
... The National Aeronautics and Space Administration (NASA) has ... disasters.,In fact it goes further than others and ... to push Earth past "critical tipping points" with "dangerous ... by NASA and the Columbia University Earth Institute appears ...
... might be the brand ambassadors of India. But they could ... happened in the case of Thirumurthy Nakka Boomaiah , ... of Tamil Nadu. ,He has been sentenced to ... a flight from London to Philadelphia and assaulting flight attendants. ...
... rubber combined with sulphur to improve its overall strength ... is difficult to reform and reuse old tyres. The ... a landfill, a process that releases heavy metals and other ... David Isaac and colleagues at Swansea University, UK, have shown ...
... technology is expected to help physicians better classify breast ... by the FDA that allows doctors to measure ... new technique may significantly reduce the need for biopsies. ... percent of biopsies turn up positive for cancer. ...
Cached Medicine News:Health News:Policy Changes Have Direct Effect on Nursing Home Care 2Health News:Policy Changes Have Direct Effect on Nursing Home Care 3Health News:FDA: New Drug for Advance Kidney Cancer 2Health News:Global Warming Disaster Closer Than Thought, Says NASA 2Health News:Global Warming Disaster Closer Than Thought, Says NASA 3Health News:Indian Engineer Sentenced for Groping Women During Flight 2
... Bird and Cronin, ... manufacturer of Patient Footwear, ... Patient Care Products. Our ... highest quality and available ...
Perfect for use in the E.R. Stabilizes collateral ligament strains in seconds and allows hand and finger function. Made from 1/8" AliPlast™ PXE. Can be scissor trimmed....
... Control of thumb motion can be difficult ... for persons with spinal cord injuries and ... to cerebral palsy or other motor or ... the thumb for control and coordination. Soft ...
... ThumWrap Splints offer support without the restriction ... mild pain or strain due to repetitive ... the rigid or the flexible stay to ... Washable and breathable, the ThumWrap Splint is ...
Medicine Products: